Esperion reports $156 to $160 million in preliminary* full-year 2025 U.S. net product sales, a 35% to 38% increase compared with full-year 2024.
Total preliminary* revenue of $400 to $408 million, a 20% to 23% increase compared with full-year 2024, and ~55% to 59% increase excluding one-time milestones.
Cash and cash equivalents of approximately $168 million* at year-end 2025.
Successful Year in 2025
Most successful year in Esperion's history driven by exceptional execution across U.S. commercial strategy and global reach.
Vision 2040 Growth Strategy
Focused on global growth of cardiometabolic franchise and expansion of pipeline into rare hepatic and renal diseases.
Financial Position Strength
Delivered meaningful growth in cardiovascular franchise and strengthened financial position.
- Esperion achieved significant progress across its pipeline in 2025, setting the stage for the ambitious Vision 2040 growth strategy.
- With a clear focus on becoming a global pharmaceutical leader, Esperion aims to transform into a multi-product, sustainable company by 2040.
- The introduction of Vision 2040 highlights Esperion's commitment to addressing a broader spectrum of unmet medical needs and leading in cardiovascular disease prevention.
Esperion's Vision 2040 roadmap signifies a shift towards becoming a multi-product global pharmaceutical company focused on innovation-driven growth and patient impact.